News
Market and company headlines
ICCMAll
Loading
06:00Oct 211 Story
04:00-08:00Oct 202 Stories
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their outstanding shares is
04:00-09:00Oct 132 Stories
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that ProSense® breast cancer cryoablation was featured in multiple scientific presentations, research posters and physician workshops at the European Society of Breast Imaging ("EUSOBI") Annual Scientific Meeting 2026, held in Maastricht, the Netherlands. Featured prese
IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting
Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation